Advances in IL-21 biology-enhancing our understanding of human disease

Current Opinion in Immunology

Volumn 34, Issue , 2015, Pages 107-115

  Tangye, Stuart G ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; STAT3 PROTEIN; INTERLEUKIN DERIVATIVE;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DISEASE SEVERITY; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOREGULATION; INFECTION SENSITIVITY; INFLAMMATORY BOWEL DISEASE; LOSS OF FUNCTION MUTATION; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; X LINKED SEVERE COMBINED IMMUNODEFICIENCY; ANIMAL; BONE MARROW CELL; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; INTERLEUKINS; MYELOID CELLS; RECEPTORS, INTERLEUKIN-21; SIGNAL TRANSDUCTION;

EID: 84925120155     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2015.02.010     Document Type: Review

References (98)

1. Leonard W.J. Cytokines and immunodeficiency diseases. Nat Rev Immunol 2001, 1:200-208.
2. Buckley R.H. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol 2004, 22:625-655.
3. Matthews D.J., Clark P.A., Herbert J., Morgan G., Armitage R.J., Kinnon C., Minty A., Grabstein K.H., Caput D., Ferrara P., et al. Function of the interleukin-2 (IL-2) receptor gamma-chain in biologic responses of X-linked severe combined immunodeficient B cells to IL-2, IL-4, IL-13, and IL-15. Blood 1995, 85:38-42.
4. Recher M., Berglund L.J., Avery D.T., Cowan M.J., Gennery A.R., Smart J., Peake J., Wong M., Pai S.Y., Baxi S., et al. IL-21 is the primary common gamma chain-binding cytokine required for human B-cell differentiation in vivo. Blood 2011, 118:6824-6835.
5. Ozaki K., Kikly K., Michalovich D., Young P.R., Leonard W.J. Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci U S A 2000, 97:11439-11444.
6. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., Johnston J., Madden K., Xu W., West J., et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000, 408:57-63.
7. Asao H., Okuyama C., Kumaki S., Ishii N., Tsuchiya S., Foster D., Sugamura K. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 2001, 167:1-5.
8. Habib T., Senadheera S., Weinberg K., Kaushansky K. The common gamma chain (gamma c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry 2002, 41:8725-8731.
9. Korn T., Bettelli E., Gao W., Awasthi A., Jager A., Strom T.B., Oukka M., Kuchroo V.K. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448:484-487.
10. Nurieva R., Yang X.O., Martinez G., Zhang Y., Panopoulos A.D., Ma L., Schluns K., Tian Q., Watowich S.S., Jetten A.M., et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007, 448:480-483.
11. Wei L., Laurence A., Elias K.M., O'Shea J.J. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem 2007, 282:34605-34610.
12. Zhou L., Ivanov I.I., Spolski R., Min R., Shenderov K., Egawa T., Levy D.E., Leonard W.J., Littman D.R. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007, 8:967-974.
13. + T cells. J Exp Med 2008, 205:1369-1379.
14. Nurieva R.I., Chung Y., Hwang D., Yang X.O., Kang H.S., Ma L., Wang Y.H., Watowich S.S., Jetten A.M., Tian Q., et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 2008, 29:138-149.
15. Ma C.S., Avery D.T., Chan A., Batten M., Bustamante J., Boisson-Dupuis S., Arkwright P.D., Kreins A.Y., Averbuch D., Engelhard D., et al. Functional STAT3 deficiency compromises the generation of human T follicular helper cells. Blood 2012, 119:3997-4008.
16. Eto D., Lao C., DiToro D., Barnett B., Escobar T.C., Kageyama R., Yusuf I., Crotty S. IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. PLoS ONE 2011, 6:e17739.
17. Luthje K., Kallies A., Shimohakamada Y., G.T T.B., Light A., Tarlinton D.M., Nutt S.L. The development and fate of follicular helper T cells defined by an IL-21 reporter mouse. Nat Immunol 2012, 13:491-498.
18. Tangye S.G., Ma C.S., Brink R., Deenick E.K. The good, the bad and the ugly-TFH cells in human health and disease. Nat Rev Immunol 2013, 13:412-426.
19. Liu S.M., King C. IL-21-producing Th cells in immunity and autoimmunity. J Immunol 2013, 191:3501-3506.
20. Coquet J.M., Skak K., Davis I.D., Smyth M.J., Godfrey D.I. IL-21 modulates activation of NKT cells in patients with stage IV malignant melanoma. Clin Transl Immunol 2013, 2:e6.
21. Spolski R., Leonard W.J. Interleukin-21: a double-edged sword with therapeutic potential. Nat Rev Drug Discov 2014, 13:379-395.
22. Di Fusco D., Izzo R., Figliuzzi M.M., Pallone F., Monteleone G. IL-21 as a therapeutic target in inflammatory disorders. Expert Opin Ther Targets 2014, 18:1329-1338.
23. Wurster A.L., Rodgers V.L., Satoskar A.R., Whitters M.J., Young D.A., Collins M., Grusby M.J. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J Exp Med 2002, 196:969-977.
24. Pesce J., Kaviratne M., Ramalingam T.R., Thompson R.W., Urban J.F., Cheever A.W., Young D.A., Collins M., Grusby M.J., Wynn T.A. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest 2006, 116:2044-2055.
25. Frohlich A., Marsland B.J., Sonderegger I., Kurrer M., Hodge M.R., Harris N.L., Kopf M. IL-21 receptor signaling is integral to the development of Th2 effector responses in vivo. Blood 2007, 109:2023-2031.
26. Vogelzang A., McGuire H.M., Yu D., Sprent J., Mackay C.R., King C. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 2008, 29:127-137.
27. Kastirr I., Maglie S., Paroni M., Alfen J.S., Nizzoli G., Sugliano E., Crosti M.C., Moro M., Steckel B., Steinfelder S., et al. IL-21 is a central memory T cell-associated cytokine that inhibits the generation of pathogenic Th1/17 effector cells. J Immunol 2014, 193:3322-3331.
28. Attridge K., Wang C.J., Wardzinski L., Kenefeck R., Chamberlain J.L., Manzotti C., Kopf M., Walker L.S. IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis. Blood 2012, 119:4656-4664.
29. Vogelzang A., McGuire H.M., Liu S.M., Gloss B., Mercado K., Earls P., Dinger M.E., Batten M., Sprent J., King C. IL-21 contributes to fatal inflammatory disease in the absence of Foxp3+ T regulatory cells. J Immunol 2014, 192:1404-1414.
30. Schmitz I., Schneider C., Frohlich A., Frebel H., Christ D., Leonard W.J., Sparwasser T., Oxenius A., Freigang S., Kopf M. IL-21 restricts virus-driven Treg cell expansion in chronic LCMV infection. PLoS Pathog 2013, 9:e1003362.
31. Karnowski A., Chevrier S., Belz G.T., Mount A., Emslie D., D'Costa K., Tarlinton D.M., Kallies A., Corcoran L.M. B and T cells collaborate in antiviral responses via IL-6, IL-21, and transcriptional activator and coactivator, Oct2 and OBF-1. J Exp Med 2012, 209:2049-2064.
32. Coquet J.M., Chakravarti S., Smyth M.J., Godfrey D.I. Cutting edge: IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitis. J Immunol 2008, 180:7097-7101.
33. Sonderegger I., Kisielow J., Meier R., King C., Kopf M. IL-21 and IL-21R are not required for development of Th17 cells and autoimmunity in vivo. Eur J Immunol 2008, 38:1833-1838.
34. + T cell expansion and function. J Exp Med 2005, 201:139-148.
35. Kasaian M.T., Whitters M.J., Carter L.L., Lowe L.D., Jussif J.M., Deng B., Johnson K.A., Witek J.S., Senices M., Konz R.F., et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 2002, 16:559-569.
36. Ma H.L., Whitters M.J., Konz R.F., Senices M., Young D.A., Grusby M.J., Collins M., Dunussi-Joannopoulos K. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma. J Immunol 2003, 171:608-615.
37. Elsaesser H., Sauer K., Brooks D.G. IL-21 is required to control chronic viral infection. Science 2009, 324:1569-1572.
38. Frohlich A., Kisielow J., Schmitz I., Freigang S., Shamshiev A.T., Weber J., Marsland B.J., Oxenius A., Kopf M. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 2009, 324:1576-1580.
39. Yi J.S., Du M., Zajac A.J. A vital role for interleukin-21 in the control of a chronic viral infection. Science 2009, 324:1572-1576.
40. Yi J.S., Ingram J.T., Zajac A.J. IL-21 deficiency influences CD8 T cell quality and recall responses following an acute viral infection. J Immunol 2010, 185:4835-4845.
41. Novy P., Huang X., Leonard W.J., Yang Y. Intrinsic IL-21 signaling is critical for CD8 T cell survival and memory formation in response to vaccinia viral infection. J Immunol 2011, 186:2729-2738.
42. Brady J., Hayakawa Y., Smyth M.J., Nutt S.L. IL-21 induces the functional maturation of murine NK cells. J Immunol 2004, 172:2048-2058.
43. Smyth M.J., Wallace M.E., Nutt S.L., Yagita H., Godfrey D.I., Hayakawa Y. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med 2005, 201:1973-1985.
44. Wang G., Tschoi M., Spolski R., Lou Y., Ozaki K., Feng C., Kim G., Leonard W.J., Hwu P. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 2003, 63:9016-9022.
45. Coquet J.M., Kyparissoudis K., Pellicci D.G., Besra G., Berzins S.P., Smyth M.J., Godfrey D.I. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol 2007, 178:2827-2834.
46. Davis I.D., Brady B., Kefford R.F., Millward M., Cebon J., Skrumsager B.K., Mouritzen U., Hansen L.T., Skak K., Lundsgaard D., et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res 2009, 15:2123-2129.
47. Schmidt H., Brown J., Mouritzen U., Selby P., Fode K., Svane I.M., Cook G.P., Mollerup D.H., Geertsen P.F. Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial. Clin Cancer Res 2010, 16:5312-5319.
48. Frederiksen K.S., Lundsgaard D., Freeman J.A., Hughes S.D., Holm T.L., Skrumsager B.K., Petri A., Hansen L.T., McArthur G.A., Davis I.D., et al. IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother 2008, 57:1439-1449.
49. Pene J., Gauchat J.F., Lecart S., Drouet E., Guglielmi P., Boulay V., Delwail A., Foster D., Lecron J.C., Yssel H. Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. J Immunol 2004, 172:5154-5157.
50. Ettinger R., Sims G.P., Fairhurst A.M., Robbins R., da Silva Y.S., Spolski R., Leonard W.J., Lipsky P.E. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol 2005, 175:7867-7879.
51. Avery D.T., Bryant V.L., Ma C.S., de Waal Malefyt R., Tangye S.G. IL-21-induced isotype switching to IgG and IgA by human naive B cells is differentially regulated by IL-4. J Immunol 2008, 181:1767-1779.
52. + T follicular helper cells. J Immunol 2007, 179:8180-8190.
53. Good K.L., Bryant V.L., Tangye S.G. Kinetics of human B cell behavior and amplification of proliferative responses following stimulation with IL-21. J Immunol 2006, 177:5236-5247.
54. Ozaki K., Spolski R., Ettinger R., Kim H.P., Wang G., Qi C.F., Hwu P., Shaffer D.J., Akilesh S., Roopenian D.C., et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol 2004, 173:5361-5371.
55. Attridge K., Kenefeck R., Wardzinski L., Qureshi O.S., Wang C.J., Manzotti C., Okkenhaug K., Walker L.S. IL-21 promotes CD4 T cell responses by phosphatidylinositol 3-kinase-dependent upregulation of CD86 on B cells. J Immunol 2014, 192:2195-2201.
56. Rodriguez-Bayona B., Ramos-Amaya A., Bernal J., Campos-Caro A., Brieva J.A. Cutting edge: IL-21 derived from human follicular helper T cells acts as a survival factor for secondary lymphoid organ, but not for bone marrow, plasma cells. J Immunol 2012, 188:1578-1581.
57. Avery D.T., Deenick E.K., Ma C.S., Suryani S., Simpson N., Chew G.Y., Chan T.D., Palendira U., Bustamante J., Boisson-Dupuis S., et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med 2010, 207:155-171.
58. Deenick E.K., Avery D.T., Chan A., Berglund L.J., Ives M.L., Moens L., Stoddard J.L., Bustamante J., Boisson-Dupuis S., Tsumura M., et al. Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells. J Exp Med 2013, 210:2739-2753.
59. Berglund L.J., Avery D.T., Ma C.S., Moens L., Deenick E.K., Bustamante J., Boisson-Dupuis S., Wong M., Adelstein S., Arkwright P.D., et al. IL-21 signalling via STAT3 primes human naive B cells to respond to IL-2 to enhance their differentiation into plasmablasts. Blood 2013, 122:3940-3950.
60. Ozaki K., Spolski R., Feng C.G., Qi C.F., Cheng J., Sher A., Morse H.C., Liu C., Schwartzberg P.L., Leonard W.J. A critical role for IL-21 in regulating immunoglobulin production. Science 2002, 298:1630-1634.
61. Zotos D., Coquet J.M., Zhang Y., Light A., D'Costa K., Kallies A., Corcoran L.M., Godfrey D.I., Toellner K.M., Smyth M.J., et al. IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med 2010, 207:365-378.
62. Bessa J., Kopf M., Bachmann M.F. Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner. J Immunol 2010, 184:4615-4619.
63. Rankin A.L., MacLeod H., Keegan S., Andreyeva T., Lowe L., Bloom L., Collins M., Nickerson-Nutter C., Young D., Guay H. IL-21 receptor is critical for the development of memory B cell responses. J Immunol 2011, 186:667-674.
64. Rasheed M.A., Latner D.R., Aubert R.D., Gourley T., Spolski R., Davis C.W., Langley W.A., Ha S.J., Ye L., Sarkar S., et al. Interleukin-21 is a critical cytokine for the generation of virus-specific long-lived plasma cells. J Virol 2013, 87:7737-7746.
65. Hagn M., Schwesinger E., Ebel V., Sontheimer K., Maier J., Beyer T., Syrovets T., Laumonnier Y., Fabricius D., Simmet T., et al. Human B cells secrete granzyme B when recognizing viral antigens in the context of the acute phase cytokine IL-21. J Immunol 2009, 183:1838-1845.
66. Yoshizaki A., Miyagaki T., DiLillo D.J., Matsushita T., Horikawa M., Kountikov E.I., Spolski R., Poe J.C., Leonard W.J., Tedder T.F. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 2012, 491:264-268.
67. Herber D., Brown T.P., Liang S., Young D.A., Collins M., Dunussi-Joannopoulos K. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 2007, 178:3822-3830.
68. Bubier J.A., Sproule T.J., Foreman O., Spolski R., Shaffer D.J., Morse H.C., Leonard W.J., Roopenian D.C. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci U S A 2009, 106:1518-1523.
69. Rankin A.L., Guay H., Herber D., Bertino S.A., Duzanski T.A., Carrier Y., Keegan S., Senices M., Stedman N., Ryan M., et al. IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice. J Immunol 2012, 188:1656-1667.
70. Spolski R., Kashyap M., Robinson C., Yu Z., Leonard W.J. IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc Natl Acad Sci U S A 2008, 105:14028-14033.
71. McGuire H.M., Walters S., Vogelzang A., Lee C.M., Webster K.E., Sprent J., Christ D., Grey S., King C. Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models. Diabetes 2011, 60:867-875.
72. Sutherland A.P., Van Belle T., Wurster A.L., Suto A., Michaud M., Zhang D., Grusby M.J., von Herrath M. Interleukin-21 is required for the development of type 1 diabetes in NOD mice. Diabetes 2009, 58:1144-1155.
73. Van Belle T.L., Nierkens S., Arens R., von Herrath M.G. Interleukin-21 receptor-mediated signals control autoreactive T cell infiltration in pancreatic islets. Immunity 2012, 36:1060-1072.
74. Young D.A., Hegen M., Ma H.L., Whitters M.J., Albert L.M., Lowe L., Senices M., Wu P.W., Sibley B., Leathurby Y., et al. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 2007, 56:1152-1163.
75. Wang L., Yu C.R., Kim H.P., Liao W., Telford W.G., Egwuagu C.E., Leonard W.J. Key role for IL-21 in experimental autoimmune uveitis. Proc Natl Acad Sci U S A 2011, 108:9542-9547.
76. McPhee C.G., Bubier J.A., Sproule T.J., Park G., Steinbuck M.P., Schott W.H., Christianson G.J., Morse H.C., Roopenian D.C. IL-21 is a double-edged sword in the systemic lupus erythematosus-like disease of BXSB. Yaa mice. J Immunol 2013, 191:4581-4588.
77. Le Coz C., Joublin A., Pasquali J.L., Korganow A.S., Dumortier H., Monneaux F. Circulating TFH subset distribution is strongly affected in lupus patients with an active disease. PLOS ONE 2013, 8:e75319.
78. Terrier B., Costedoat-Chalumeau N., Garrido M., Geri G., Rosenzwajg M., Musset L., Klatzmann D., Saadoun D., Cacoub P. Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus. J Rheumatol 2012, 39:1819-1828.
79. Wang L., Zhao P., Ma L., Shan Y., Jiang Z., Wang J., Jiang Y. Increased interleukin 21 and follicular helper T-like cells and reduced interleukin 10+ B cells in patients with new-onset systemic lupus erythematosus. J Rheumatol 2014, 41:1781-1792.
80. Feng X., Wang D., Chen J., Lu L., Hua B., Li X., Tsao B.P., Sun L. Inhibition of aberrant circulating Tfh cell proportions by corticosteroids in patients with systemic lupus erythematosus. PLoS ONE 2012, 7:e51982.
81. He J., Tsai L.M., Leong Y.A., Hu X., Ma C.S., Chevalier N., Sun X., Vandenberg K., Rockman S., Ding Y., et al. Circulating precursor CCR7(lo)PD-1(hi) CXCR5(+) CD4(+) T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity 2013, 39:770-781.
82. Arroyo-Villa I., Bautista-Caro M.B., Balsa A., Aguado-Acin P., Bonilla-Hernan M.G., Plasencia C., Villalba A., Nuno L., Puig-Kroger A., Martin-Mola E., et al. Constitutively altered frequencies of circulating follicullar helper T cell counterparts and their subsets in Rheumatoid Arthritis. Arthritis Res Ther 2014, 16:500.
83. Liu R., Wu Q., Su D., Che N., Chen H., Geng L., Chen J., Chen W., Li X., Sun L. A regulatory effect of IL-21 on T follicular helper-like cell and B cell in rheumatoid arthritis. Arthritis Res Ther 2012, 14:R255.
84. Wang J., Shan Y., Jiang Z., Feng J., Li C., Ma L., Jiang Y. High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis. Clin Exp Immunol 2013, 174:212-220.
85. Xu X., Shi Y., Cai Y., Zhang Q., Yang F., Chen H., Gu Y., Zhang M., Yu L., Yang T. Inhibition of increased circulating Tfh cell by anti-CD20 monoclonal antibody in patients with type 1 diabetes. PLOS ONE 2013, 8:e79858.
86. Kenefeck R., Wang C.J., Kapadi T., Wardzinski L., Attridge K., Clough L.E., Heuts F., Kogimtzis A., Patel S., Rosenthal M., et al. Follicular helper T cell signature in type 1 diabetes. J Clin Invest 2015, 125:292-303.
87. Sawalha A.H., Kaufman K.M., Kelly J.A., Adler A.J., Aberle T., Kilpatrick J., Wakeland E.K., Li Q.Z., Wandstrat A.E., Karp D.R., et al. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis 2008, 67:458-461.
88. Webb R., Merrill J.T., Kelly J.A., Sestak A., Kaufman K.M., Langefeld C.D., Ziegler J., Kimberly R.P., Edberg J.C., Ramsey-Goldman R., et al. A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum 2009, 60:2402-2407.
89. Flanagan S.E., Haapaniemi E., Russell M.A., Caswell R., Lango Allen H., De Franco E., McDonald T.J., Rajala H., Ramelius A., Barton J., et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet 2014, 46:812-814.
90. Milner J.D., Vogel T.P., Forbes L., Ma C.A., Stray-Pedersen A., Niemela J.E., Lyons J.J., Engelhardt K.R., Zhang Y., Topcagic N., et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood 2015, 125:591-599.
91. Haapaniemi E.M., Kaustio M., Rajala H.L., van Adrichem A.J., Kainulainen L., Glumoff V., Doffinger R., Kuusanmaki H., Heiskanen-Kosma T., Trotta L., et al. Autoimmunity, hypogammaglobulinemia, lymphoproliferation and mycobacterial disease in patients with dominant activating mutations in STAT3. Blood 2015, 125:639-648.
92. Kotlarz D., Zietara N., Uzel G., Weidemann T., Braun C.J., Diestelhorst J., Krawitz P.M., Robinson P.N., Hecht J., Puchalka J., et al. Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome. J Exp Med 2013, 210:433-443.
93. Stepensky P., Keller B., Abuzaitoun O., Shaag A., Yaacov B., Unger S., Seidl M., Rizzi M., Weintraub M., Elpeleg O., et al. Extending the clinical and immunological phenotype of human Interleukin-21 receptor deficiency. Haematologica 2014, 10.3324/haematol.2014.112508.
94. Erman B., Bilic I., Hisrchmugl T., Salzer E., Ayvaz Ça da D., Esenboga S., Akcoren Z., Sanal Ö., Tezcan I., Boztug K. Combined immunodeficiency with predominant CD4 lymphopenia and sclerosing cholangitis caused by a novel loss-of-function mutation affecting IL21R. Haematologica 2015, (in press).
95. Kotlarz D., Zietara N., Milner J.D., Klein C. Human IL-21 and IL-21R deficiencies: two novel entities of primary immunodeficiency. Curr Opin Pediatr 2014, 26:704-712.
96. Salzer E., Kansu A., Sic H., Majek P., Ikinciogullari A., Dogu F.E., Prengemann N.K., Santos-Valente E., Pickl W.F., Bilic I., et al. Early-onset inflammatory bowel disease and common variable immunodeficiency-like disease caused by IL-21 deficiency. J Allergy Clin Immunol 2014, 133. 1651-1659 e1612.
97. Spolski R., Kim H.P., Zhu W., Levy D.E., Leonard W.J. IL-21 mediates suppressive effects via its induction of IL-10. J Immunol 2009, 182:2859-2867.
98. Kotlarz D., Beier R., Murugan D., Diestelhorst J., Jensen O., Boztug K., Pfeifer D., Kreipe H., Pfister E.D., Baumann U., et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 2012, 143:347-355.